In this issue:
ctDNA is a blood-based biomarker prognostic for recurrence
Frontline pembrolizumab superior to chemotherapy for HRQoL outcomes in MSI-H/dMMR
PRODIGE 23: total neoadjuvant therapy reduces the risk of recurrence
Outcomes following major resection for older Australian patients
No benefit to the addition of oxaliplatin to fluoropyrimidine adjuvant therapy in older patients
Radiation plus immune checkpoint inhibition not suitable for MSS disease
REGOMUNE fails to demonstrate response to regorafenib-avelumab in MSS disease
Frontline dual anti-angiogenesis with bevacizumab/trebananib for metastatic CRC
Sorafenib plus capecitabine in previously treated metastatic disease
IDEA Collaboration study results change practice in France
Please login below to download this issue (PDF)